Clinical outcomes of patients with diabetes and atrial fibrillation treated with apixaban: results from the ARISTOTLE trial | Zendy

Justin A. Ezekowitz | Zendy; Basil S. Lewis | Zendy; Renato D. Lópes | Zendy; Daniel Wojdyla | Zendy; John J.V. McMurray | Zendy; Michael Hanna | Zendy; Dan Atar | Zendy; M. Cecilia Bahit | Zendy; Matyàs Keltai | Zendy; José LópezSendón | Zendy; Prem Pais | Zendy; Witold Rużyłło | Zendy; Lars Wallentin | Zendy; Christopher B. Granger | Zendy; John H. Alexander | Zendy

Open Access

Clinical outcomes of patients with diabetes and atrial fibrillation treated with apixaban: results from the ARISTOTLE trial

Author(s) -

Justin A. Ezekowitz,

Basil S. Lewis,

Renato D. Lópes,

Daniel Wojdyla,

John J.V. McMurray,

Michael Hanna,

Dan Atar,

M. Cecilia Bahit,

Matyàs Keltai,

José LópezSendón,

Prem Pais,

Witold Rużyłło,

Lars Wallentin,

Christopher B. Granger,

John H. Alexander

Publication year - 2015

Publication title -

european heart journal - cardiovascular pharmacotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.895

H-Index - 26

eISSN - 2055-6845

pISSN - 2055-6837

DOI - 10.1093/ehjcvp/pvu024

Subject(s) - apixaban , atrial fibrillation , medicine , diabetes mellitus , clinical trial , cardiology , randomized controlled trial , intensive care medicine , warfarin , rivaroxaban , endocrinology

We compared clinical outcomes in patients with AF with and without diabetes in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research